NYSE:CLDI Calidi Biotherapeutics (CLDI) Stock Price, News & Analysis $0.25 +0.01 (+5.60%) Closing price 07/3/2025 03:49 PM EasternExtended Trading$0.25 0.00 (0.00%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Calidi Biotherapeutics Stock (NYSE:CLDI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Calidi Biotherapeutics alerts:Sign Up Key Stats Today's Range$0.23▼$0.2550-Day Range$0.22▼$0.5052-Week Range$0.20▼$3.89Volume551,055 shsAverage Volume1.01 million shsMarket Capitalization$7.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California. Read More Calidi Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreCLDI MarketRank™: Calidi Biotherapeutics scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Calidi Biotherapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Calidi Biotherapeutics are expected to grow in the coming year, from ($4.48) to ($0.88) per share. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.23% of the float of Calidi Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverCalidi Biotherapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Calidi Biotherapeutics has recently increased by 24.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCalidi Biotherapeutics does not currently pay a dividend.Dividend GrowthCalidi Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.23% of the float of Calidi Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverCalidi Biotherapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Calidi Biotherapeutics has recently increased by 24.61%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest6 people have searched for CLDI on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Calidi Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.70% of the stock of Calidi Biotherapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.53% of the stock of Calidi Biotherapeutics is held by institutions.Read more about Calidi Biotherapeutics' insider trading history. Receive CLDI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calidi Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDI Stock News HeadlinesCalidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Shareholder Letter from CEOJune 27, 2025 | finanznachrichten.deCalidi Biotherapeutics Announces Shareholder Letter from CEOJune 27, 2025 | globenewswire.comThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.July 5 at 2:00 AM | Crypto Swap Profits (Ad)Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational HighlightsMay 16, 2025 | finanznachrichten.deCalidi Biotherapeutics Strengthens Leadership Team and Advances Antitumor Virotherapy Platform with New CEO and Chief Medical Officer AppointmentsMay 16, 2025 | nasdaq.comCalidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational HighlightsMay 15, 2025 | tmcnet.comCalidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual MeetingApril 28, 2025 | finance.yahoo.comCalidi reports inducement grant unders NYSE American guideApril 26, 2025 | markets.businessinsider.comSee More Headlines CLDI Stock Analysis - Frequently Asked Questions How have CLDI shares performed this year? Calidi Biotherapeutics' stock was trading at $1.15 at the beginning of 2025. Since then, CLDI stock has decreased by 78.5% and is now trading at $0.2470. How were Calidi Biotherapeutics' earnings last quarter? Calidi Biotherapeutics, Inc. (NYSE:CLDI) released its earnings results on Tuesday, November, 12th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.20. When did Calidi Biotherapeutics' stock split? Calidi Biotherapeutics shares reverse split before market open on Monday, July 15th 2024.The 1-10 reverse split was announced on Monday, July 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Calidi Biotherapeutics? Shares of CLDI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Calidi Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Calidi Biotherapeutics investors own include ARMOUR Residential REIT (ARR), AGNC Investment (AGNC), Avino Silver & Gold Mines (ASM), Carlyle Secured Lending (CGBD), Devon Energy (DVN), Hercules Capital (HTGC) and Main Street Capital (MAIN). Company Calendar Last Earnings11/12/2024Today7/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:CLDI Previous SymbolNYSE:CLDI CIK1855485 Webcalidibio.com Phone858-794-9600FaxN/AEmployees38Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.22 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-344.45% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.32) per share Price / Book-0.11Miscellaneous Outstanding Shares31,793,000Free Float20,039,000Market Cap$7.85 million OptionableN/A Beta0.95 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NYSE:CLDI) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.